RT Journal Article SR Electronic T1 Transmission of SARS-CoV-2 from Children and Adolescents JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.10.10.20210492 DO 10.1101/2020.10.10.20210492 A1 Victoria T. Chu A1 Anna R. Yousaf A1 Karen Chang A1 Noah G. Schwartz A1 Clinton J. McDaniel A1 Christine M. Szablewski A1 Marie Brown A1 Kathryn Winglee A1 Scott H. Lee A1 Zhaohui Cui A1 Adebola Adebayo A1 Tiffiany Aholou A1 Minal M. Amin A1 Peter Aryee A1 Cindy Castaneda A1 Trudy Chambers A1 Amy C. Fleshman A1 Christin Goodman A1 Tony Holmes A1 Asha Ivey-Stephenson A1 Emiko Kamitani A1 Susan Katz A1 Jennifer K. Knapp A1 Maureen Kolasa A1 Maranda Lumsden A1 Erin Mayweather A1 Asfia Mohammed A1 Anne Moorman A1 Alpa Patel-Larson A1 Lara Perinet A1 Mark Pilgard A1 Deirdre D. Pratt A1 Shanica Railey A1 Jaina Shah A1 Dawn Tuckey A1 Emilio Dirlikov A1 Dale A. Rose A1 Julie Villanueva A1 Alicia M. Fry A1 Aron J. Hall A1 Hannah L. Kirking A1 Jacqueline E. Tate A1 Cherie L. Drenzek A1 Tatiana M. Lanzieri A1 Rebekah J. Stewart YR 2020 UL http://medrxiv.org/content/early/2020/10/13/2020.10.10.20210492.abstract AB A better understanding of SARS-CoV-2 transmission from children and adolescents is crucial for informing public health mitigation strategies. We conducted a retrospective cohort study among household contacts of primary cases defined as children and adolescents aged 7⍰19 years with laboratory evidence of SARS-CoV-2 infection acquired during an overnight camp outbreak. Among household contacts, we defined secondary cases using the Council of State and Territorial Epidemiologists definition. Among 526 household contacts of 224 primary cases, 48 secondary cases were identified, corresponding to a secondary attack rate of 9% (95% confidence interval [CI], 7%–12%). Our findings show that children and adolescents can transmit SARS-CoV-2 to adult contacts and other children in a household setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was wholly supported by the U.S. Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This protocol was reviewed by CDC and the Georgia Department of Public Health human subjects research officials. The investigation was deemed non-research as part of the COVID-19 public health response.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data to reproduce results will be available upon peer-reviewed publication and request.